Biomarker testing is used among diagnosed patients with non-small cell lung cancer (NSCLC) to determine the presence of specific mutations or proteins associated with cancer. It ensures that patients get matched to the right treatment at the right time, based on their biomarker test results. The results can also provide a complete overview of the therapies and clinical trials available to them specific to their biomarker(s). It should be noted that biomarker test reports are not the same across all labs that run them. This booklet, therefore, will cover the general information that most biomarker test reports contain. It explains the different biomarkers that cancers are tested for, what the results mean, how available therapy options are reported, and how to evaluate the clinical trial options in partnership with your healthcare provider. Read more.
We are a group of lung cancer patients with EGFR mutations who have developed resistance to at least one targeted treatment drug, or who face probable resistance in the future. Caregivers are also welcome. We are here to share treatment experiences, information about clinical trials, breaking news about research developments, and other information with each other.